Non-Hodgkin Lymphoma Archives - Page 2 of 23

Burkitt Lymphoma: Clinical, Pathologic, and Genomic Features in Adults

By

December 17, 2020

Experts discuss clinical, pathologic, and genomic features of Burkitt lymphoma in adults, as well as standard and emerging treatment options for this patient population.

CRS and HIPEC appear to have promising data when used in the optimal patient population.

ASH 2020

Intensive Chemotherapy Tolerable, Efficacious in HIV-Associated Burkitt Lymphoma

By

Lauren Dembeck, PhD

December 15, 2020

Among patients with HIV-associated Burkitt lymphoma, intensive regimens containing rituximab may be linked to favorable survival outcomes.

A person holding 2 white pills in their hand.

ASH 2020

Mantle Cell Lymphoma: Long-Extending Remissions With Lenalidomide, Rituximab

By

Lauren Dembeck, PhD

December 15, 2020

Initial treatment of mantle cell lymphoma with lenalidomide and rituximab may result in significant complete response rates and durable lengths of remission.

ASH 2020

Durable Responses Seen With Odronextamab in Refractory B-Cell NHLs

By

Andrea S. Blevins Primeau, PhD, MBA

December 9, 2020

Encouraging antitumor activity and durable responses were reported with odronextamab among patients with highly refractory B-cell NHLs.

Enrichment of an early memory CD8+ T-cell phenotype in patients’ blood was predictive of their response to CAR-T therapy in CLL, NHL, and MM.

Lymphoma

Risk Factors for Early Relapse of DLBCL After CAR-T Therapy

By

Andrea S. Blevins Primeau, PhD, MBA

November 30, 2020

Nearly half of all relapses occurred within the first month of CAR-T infusion.

Leukemia, Lymphoma

Postmarketing Observational Study of Tisagenlecleucel for ALL or NHL Yields Promising Results

By

Susan Moench, PhD, PA-C

November 24, 2020

Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.

Small studies, the absence of subtypes, and a historical lack of genetic information has stopped past studies from triggering meaningful public health change, a review asserts.

Lymphoma

Why It’s Been So Hard to Conclusively Link Environmental Factors to Non-Hodgkin Lymphoma

By

Julia Faith Sklar

November 2, 2020

Small studies, the absence of subtypes, and a historical lack of genetic information has stopped past studies from triggering meaningful public health change, a review asserts.